Description
Background:
Flotetuzumab is an investigationalbispecific antibody designed for the treatment of acute myeloid leukemia. Designed to bind to CD3e and CD123 engineered in a DART format. CD3-engaging bispecific molecules bind both tumor and effector cells to promote an immunologic synapse and redirect polyclonal effectors to kill tumor cells in an major histocompatibility complex (MHC)-independent fashion.
Intended Use:
For Estimation of Flotetuzumab in human serum and plasma. Krishgen’s range of KRIBIOLISA kits are developed using the high quality raw materials and are thoroughly validated for accuracy and precison. They allow quantification of serum or plasma protein drug levels, and can be used for biosimilar and generics research to understand pharmacokinetic properties of the drug. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us for optimisation.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!